As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
ApexOnco Front Page
Recent articles
Summit and Nuvalent have scored prized plenary spots.
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
The Avanzar study could read out shortly.
The company reckons its immunotherapy could improve on Keytruda.
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.
Satri-cel is filed for gastric cancer approval in China.
“We need all the capital we can get our hands on," the company states.
